- Alzheimer’s therapeutics refer to treatments developed to manage the symptoms of Alzheimer’s disease, slow its progression, and improve the quality of life for patients. These include symptomatic treatments, such as cholinesterase inhibitors and glutamate regulators, as well as disease-modifying therapies that aim to alter the course of the disease
- The market for Alzheimer’s therapeutics has been expanding rapidly, driven by the growing global prevalence of the disease, particularly as the population ages
- The demand for Alzheimer’s therapeutics is significantly influenced by the rising number of individuals diagnosed with the disease, especially in regions with aging populations such as North America and Europe. As these regions see an increasing number of Alzheimer's patients, there is heightened focus on developing effective treatments. Advancements in research and the approval of new drugs also contribute to market growth
- For instance, In North America, the approval of Aduhelm by the FDA in June 2021 marked a significant milestone in Alzheimer's treatment. This drug, developed by Biogen, targets amyloid plaques, a hallmark of Alzheimer's, offering a new treatment option and driving the demand for disease-modifying therapies
- Overall, the Alzheimer's therapeutics market is expected to grow significantly as demand for innovative treatments rises alongside the aging global population
